ABSTRACT
Familial hypercholesterolaemia (FH) is a highly prevalent silent disease with known genetic causes and poor prognosis if undiagnosed into adulthood. Characterised by high levels of total cholesterol and low-density lipoprotein cholesterol from birth, the majority of cases that fit the clinical criteria for FH do not present mutations in the disease associated genes and seem to result from polygenic and/or environmental causes. In this study we have addressed the heterogeneity of extended blood biochemical and genetic parameters across a cohort of children using an unsupervised hierarchical clustering approach. In addition to correctly classifying individuals into the two classes recognized in clinical studies for familial hypercholesterolaemia (with and without genetic diagnosis), a subset of patients with mixed characteristics was systematically identified as representing a third category. The careful analysis of biochemical, genetic, and anthropomorphic characteristics that constitute hallmarks of each group provides detailed insights into the characteristics of each group, contributing to unravel the complexity of FH and dyslipidaemic phenotypes. The results presented here may assist in the future identification of novel biomarkers to efficiently identify FH+ individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by UIDB/04046/2020 and UIDP/04046/2020 Centre grants from FCT, Portugal (to BioISI). MC is recipient of a fellowship from the BioSys Ph.D. programme PD65-2012 (Ref PD/ BD/114387/2016) from FCT (Portugal).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The National Institute of Health (Instituto Nacional de Saude Dr. Ricardo Jorge, Portugal) Ethic Committee and National Data Protection Commission (Portugal) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at the GitHub repository.
